Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 3rd Preview)
-
Angelman syndrome clinical failure
Ultragenyx said its antisense oligonucleotide therapy GTX-102 for Angelman syndrome failed to show benefit in a Phase 3 trial, dealing a major blow to the company’s late-stage pipeline. The results follow earlier hopes after positive performance in earlier studies, and they remove a key profitability path for a biotech that has largely relied on ultra-rare disease revenue. As reported by STAT+, the Phase 3 program compared GTX-102 against a sham treatment and found no evidence of improvement on trial endpoints. The setback also highlights the difficulty of translating early signals in severe neurodevelopmental disorders into confirmatory data for regulatory approval. For Ultragenyx, the immediate impact is strategic and financial: investors had leaned on Angelman to drive future growth, while the company’s approved portfolio is concentrated in very rare indications. The company will need to reassess development plans for GTX-102 and how to redeploy resources across remaining assets.
-
Huntington gene therapy seeks FDA priority review
UniQure moved a major regulatory step forward in Huntington’s disease by submitting applications to the FDA and the UK’s MHRA for AMT-130, a gene therapy the company says could become the first to treat the disease’s underlying cause. UniQure is requesting priority review from FDA, targeting a decision in roughly eight months, and it also completed a UK submission. The filing is based on previously reported three-year data indicating AMT-130 could significantly slow disease progression. The program follows a year of regulatory and ethical scrutiny over UniQure’s control strategy, including FDA requests for a new double-blind trial with a sham surgery control group. The submission underscores how gene-therapy approvals can hinge not only on efficacy readouts, but also on trial design details for surgical therapies where appropriate controls are difficult to implement.
-
Teva’s celiac disease gluten challenge results
Teva reported that its investigational antibody TEV’408 succeeded in a mid-stage celiac disease gluten challenge study by significantly reducing intestinal damage. In the trial, participants ate gluten daily after receiving the drug, and TEV’408 showed statistically significant and clinically meaningful protection compared with placebo over eight weeks. Teva positioned the data as advancing “pipeline-in-a-product potential,” while also referencing earlier work in vitiligo as supportive evidence for broader development. Teva said analyses from an ongoing Phase 2a study are underway, with additional results expected to be shared at future scientific meetings. With no FDA-approved therapies currently for celiac disease, the company’s readout adds pressure to the competitive race to deliver the first approved treatment that can prevent gluten-induced injury.
-
Roche expands B-cell franchise with Simcere trispecific TCE deal
Roche agreed to license Simcere Zaiming’s preclinical trispecific T-cell engager SIM-0660 in a deal worth up to $1.53 billion, with a $75 million upfront payment. The asset targets CD79a/CD19 on B cells and CD3 on T cells, aiming to drive T-cell mediated killing while limiting cytokine-release risk observed in earlier generations of T-cell engager platforms. Under the terms, Roche obtains exclusive global rights to develop, manufacture and commercialize SIM-0660, while Simcere is eligible for development, regulatory, and commercial milestones. The molecule was described as being aimed at B-cell-mediated diseases including lymphoma and autoimmune conditions. The agreement signals continued big-pharma interest in next-generation bispecific and trispecific engagement strategies, particularly where platforms emphasize selectivity to improve safety.
-
Novartis pushes remibrutinib into MS Phase 3 wins
Novartis reported success for its BTK inhibitor remibrutinib (Rhapsido) in two large Phase 3 multiple sclerosis studies, describing superiority over Aubagio in reducing annualized relapse rates and inflammatory brain lesions. The company also said the treatment delivered clinically meaningful effects on disability progression and did not impact liver safety, a key issue in BTK inhibitor development. Novartis did not provide detailed study results in the disclosure, but the company intends to share the findings with regulators. Analysts and investors will focus on the full dataset, including safety monitoring and the robustness of efficacy across key MS subgroups. The results potentially expand remibrutinib’s commercial scope beyond its existing approval for chronic skin hives into MS, as Novartis seeks late-stage assets to offset patent expirations.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.